
Breaking Boundaries: Selas Life Sciences Achieves Target Enrollment in Phase 3 Regal Trial for Galinpepimut-S in Acute Myeloid Leukemia, Excluding China
Independent Data Monitoring Committee Scheduled to Meet This Quarter SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acut… New York, Nov. 29, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel…